Weeding Out Pipeline “Dogs” Early Can Be As Valuable As A Blockbuster
Eliminating "bad" compounds from the pipeline early in the development process can generate as much value as picking a blockbuster, McKinsey Partner Rodney Zemmel suggested Sept. 26
You may also be interested in...
The decline in new molecular entity approvals may reflect decreasing interest by industry in the development of "me too" agents, FDA Office of Medical Policy Director Robert Temple said
Expanded approaches to Phase II development have reduced Phase III attrition rates, but in doing so, have also created a new set of challenges for pharmaceutical companies, according to Pfizer Senior VP-Science & Technology Peter Corr
Amgen's strategy of conducting head-to-head trials of its products against current standards of care pre-approval indicates the firm is focusing on effectively positioning products in an increasingly competitive, Medicare-oriented reimbursement environment